Efficacy and Tolerability of Risperidone, Yokukansan, and Fluvoxamine for the Treatment of Behavioral and Psychological Symptoms of Dementia: A Blinded, Randomized Trial
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The descriptive term behavioral and psychological symptoms of dementia (BPSD) is used to cover a range of noncognitive disturbances including anxiety, depression, irritability, aggression, agitation, eating disorders, and inappropriate social or sexual behaviors. Behavioral and psychological symptoms of dementia are seen in about 90% of patients with dementia. We aimed to compare the efficacy and tolerability of risperidone, yokukansan, and fluvoxamine used for BPSD in elderly patients with dementia. Ninety inpatients with dementia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria were investigated in Sato Hospital, Koutokukai. We conducted an 8-week, rater-blinded, randomized trial, administering flexibly dosed risperidone, yokukansan, or fluvoxamine. Primary outcome measures were Neuropsychiatric Inventory in Nursing Home Version total score and its items. Secondary outcome measures were cognitive function measured by Mini-Mental State Examination and daily life function measured by Functional Independence Measure (FIM). Neurological adverse effects were measured by the Drug-Induced Extra-Pyramidal Symptoms Scale. At the end of the study, we analyzed 76 patients (92.7%). Mean Neuropsychiatric Inventory in Nursing Home Version total score decreased in all 3 drug groups, with no significant between-group differences. Mini-Mental State Examination and Functional Independence Measure scores did not change significantly. Drug-Induced Extra-Pyramidal Symptoms Scale scores did not change in the yokukansan and fluvoxamine groups, but increased significantly in the risperidone group. Risperidone, yokukansan, and fluvoxamine were equally effective in the treatment of BPSD in elderly patients. However, yokukansan or fluvoxamine for BPSD showed a more favorable profile in tolerability compared with risperidone. This trial is registered at UMIN Clinical Trials Registry (identifier: UMIN000006146).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“A meta-analysis of randomized, placebo-controlled trials has suggested a significantly higher risk of death with atypical antipsychotic drug treatment for dementia than with placebo treatment.(30) In April 2005, the US Food and Drug Administration requested a health advisory warning to the prescription information for…”
BackgroundSchneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia
Schneider, L. S., Pollock, V. E., & Lyness, S. A. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb02407.x · Cited by 650 · cited 9×
“Conventional antipsychotics have demonstrated modest but consistent effectiveness against BPSD.(6) However, elderly patients with dementia are particularly sensitive to adverse events (AEs), such as extrapyramidal symptoms (EPSs) and cognitive decline.”
BackgroundInfluentialRisk of Mortality Among Individual Antipsychotics in Patients With Dementia
Kales, H. C., Kim, H. M., Zivin, K., Valenstein, M., Seyfried, L. S., Chiang, C., Cunningham, F., Schneider, L. S., & Blow, F. C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11030347 · Cited by 384
Pollock, B. G., Mulsant, B. H., Rosen, J., Sweet, R. A., Mazumdar, S., Bharucha, A., Marin, R., Jacob, N. J., Huber, K. A., Kastango, K. B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.460 · Cited by 327
Donepezil for the Treatment of Agitation in Alzheimer's Disease
Howard, R. J., Juszczak, E., Ballard, C. G., Bentham, P., Brown, R. G., Bullock, R., Burns, A. S., Holmes, C., Jacoby, R., Johnson, T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066583 · Cited by 327 · cited 1×
“However, another report showed that donepezil was not more effective than placebo in treating agitation in AD patients.(4) Currently, the most common drug therapy for BPSD is the use of antipsychotics, antidepressants, antiepileptics, or benzodiazepines.”
Behavioral and Psychologic Symptoms in Different Types of Dementia
Chiu, M.-J., Chen, T.-F., Yip, P.-K., Hua, M.-S., & Tang, L.-Y. (2006) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60150-9 · Cited by 136 · cited 1×
“Behavioral and psychological symptoms of dementia are seen in about 90% of patients with dementia.(2) We know that older people with dementia enter nursing homes or similar institutions because caregivers can no longer manage their BPSD.”
Background
Cited by
Antidepressants for treating depression in dementia
Dudas, R., Malouf, R., McCleery, J., & Dening, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944.pub2 · Cited by 175
Watt, J. A., Goodarzi, Z., Veroniki, A. A., Nincic, V., Khan, P. A., Ghassemi, M., Thompson, Y., Tricco, A. C., & Straus, S. E. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0993 · Cited by 159
Watt, J. A., Goodarzi, Z., Veroniki, A. A., Nincic, V., Khan, P. A., Ghassemi, M., Lai, Y., Treister, V., Thompson, Y., Schneider, R., et al. (2021) · BMJ · doi:10.1136/bmj.n532 · Cited by 143
Metadata
- Authors
- Teranishi, M., Kurita, M., Nishino, S., Takeyoshi, K., Numata, Y., Sato, T., Tateno, A., & Okubo, Y.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2013-10
- Volume
- 33
- Issue
- 5
- Pages
- 600-607
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1987181044
- Cited by
- 53
- References
- 7
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Tolerability of Risperidone, Yokukansan, and Fluvoxamine for the Treatment of Behavioral and Psychological Symptoms of Dementia: A Blinded, Randomized Trial. https://app.cochat.ai/papers/10.1097/jcp.0b013e31829798d5
- The paper
- Teranishi, M., Kurita, M., Nishino, S., Takeyoshi, K., Numata, Y., Sato, T., Tateno, A., & Okubo, Y. (2013). Efficacy and Tolerability of Risperidone, Yokukansan, and Fluvoxamine for the Treatment of Behavioral and Psychological Symptoms of Dementia: A Blinded, Randomized Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31829798d5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.